Andrew Furness, MD, PhD, Royal Marsden Hospital, London, UK, discusses the potential of TIL (tumor-infiltrating lymphocyte) therapy for melanoma, emphasizing its immunogenic nature, which allows for the generation of TIL products from tumor tissue. He highlights the advantage of expanding TILs that recognize various tumor-associated antigens, although challenges exist in implementing this therapy as standard care, particularly regarding regulatory issues surrounding living cell products. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
